IP Library Granted Patent US 8,278,072
Granted Patent B1
US 8,278,072 · App. 12/274,142 · Granted Oct 2, 2012

Method for synthesis of sialylated products using reversible sialylation

Assignees: Health Research, Inc.; The Research Foundation of State University of New York
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,278,072
App. No.
12/274,142
Granted
Oct 2, 2012
Kind
B1
Abstract

A method for producing sialylated molecules based on reverse sialylation that catalytically transfers the sialic acid moiety of sialylated donors to nucleotide monophosphates or transfer sialic acid moieties from sialylated donors to acceptor glycoproteins or glycolipids.

Claims (15)

1. A method for sialylating an acceptor glycoconjugate comprising the steps of admixing in a vessel the following components to form a reaction mixture:

a) a sialic acid donor other than a sialic acid-5′-nucleotide monophosphate (NMP);

b) an acceptor glycoconjugate; and

c) catalytic amount of exogenous mammalian ST3Gal-II sialyltransferase, under conditions such that a sialylated acceptor glycoconjugate is formed in the reaction mixture.

2. The method of claim 1 , wherein the sialic acid donor is selected from the group consisting of glycoprotein and glycolipid.

3. The method of claim 2 , wherein the glycoprotein is selected from the group consisting of mucin core-2 glycoprotein, mucin core-1 glycoprotein, fetuin, and Cowper's gland mucin (CGM).

4. The method of claim 2 , wherein the glycolipid is a ganglioside.

5. The method of claim 1 , wherein the acceptor glycoconjugate is selected from the group consisting of glycoprotein and glycolipid.

6. The method of claim 1 , wherein the mammalian ST3Gal-II sialyltransferase is selected from the group consisting of recombinant rat ST3Gal-II and human ST3Gal-II.

7. The method of claim 1 , wherein the conditions comprise a pH from 5.0 to 6.0.

8. The method of claim 1 , wherein the conditions comprise a pH of 5.6.

9. The method of claim 1 , wherein the sialic acid donor has a detectable label incorporated into the sialic acid moiety that is transferred to the acceptor glycoprotein.

10. The method of claim 9 , wherein the detectable label is a radioactive isotope.

11. The method of claim 10 , wherein the radioactive isotope is selected from the group consisting of tritium ( 3 H) and 14 C.

12. The method of claim 1 , wherein the reaction mixture further comprises 5′-cytidine monophosphate.

Assignments (4)
CONFIRMATORY LICENSE Recorded Jan 26, 2010
From: ROSWELL PARK CANCER INSTITUTE
To: US ARMY, SECRETARY OF THE ARMY
Reel/Frame 023847/0529 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2009
From: NEELAMEGHAM, SRIRAM
To: THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK
Reel/Frame 022519/0266 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 8, 2009
From: MATTA, KHUSHI L.; CHANDRASEKARAN, EDAYA V.; XUE, JUN
To: HEALTH RESEARCH, INC.
Reel/Frame 022519/0325 →
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Mar 3, 2009
From: ROSWELL PARK CANCER INSTITUTE
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 022336/0960 →
Continuity (1)
Provisional Application 60989030 · Nov 19, 2007